Northwest Biotherapeutics Inc. announced annual meeting of stockholders to be held on September 4, 2009, to amend the company's seventh amended and restated certificate of incorporation to increase the number of authorized shares of common stock of the company from 100,000,000 to 150,000,000.

Northwest Biotherapeutics Inc., Annual General Meeting, Sep 04, 2009, at 11:00 US Eastern Time. Location: 7600 Wisconsin Avenue, Suite 700, Bethesda, MD 20814,United States. Agenda: To elect one member to board of directors to serve as Class II director for a term of three years; to amend the company's seventh amended and restated certificate of incorporation to increase the number of authorized shares of common stock of the company from 100,000,000 to 150,000,000; to seek shareholder approval to de-list from the London Stock Exchange's AIM Market; and to transact such other business as may properly come before the annual meeting or any adjournments or postponements of the annual meeting.

Northwest Biotherapeutics Inc. announced that it will seek shareholder approval for the Company to cancel its listing on the London Stock Exchange's AIM market (AIM) (the De-listing). The Company plans to continue its listing in the U.S., on the NASD Over the Counter Bulletin Board Market (U.S. listing), and plans to file an S1 registration statement under which the stock held on AIM may become tradable on the US market. After much review and evaluation, the Company has concluded that it is in the best interests of the Company and its shareholders to de-list from AIM. The reason for this is that the high direct costs of maintaining the Company’s AIM listing. Also, the operational and legal difficulties of being subject to two different regulatory regimes in two different countries, under which the Company has faced conflicting requirements on an ongoing basis and the management time taken up with the Company’s AIM listing are also the reasons. Also, the reason is the lack of significant liquidity or other current benefits from the Company’s AIM listing; and the ability to continue the Company’s U.S. listing, unaffected by the De-listing from AIM. The annual meeting of the Company's shareholders will be convened shortly and the relevant circular and proxy materials will be mailed to all of the Company's shareholders in advance of this meeting. One of the purposes of the meeting and the circular and proxy material is to explain the rationale behind the proposed de-listing and consolidation of trading in the Company's shares on a single market in the U.S. Shareholders will be asked to vote at the annual meeting or through proxies on a resolution to approve the de-listing.